{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-033144","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.703039+00:00","generated_at":"2026-05-31T08:38:59.742485+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LIXTE reports Roche-backed trial, new CMO, and SCLC trial termination","bullets":["New clinical trial with Netherlands Cancer Institute, supported by Roche, testing LB-100 + atezolizumab in metastatic colorectal cancer.","Dr. Jan Schellens appointed Chief Medical Officer effective Aug 1, 2024; 25+ years oncology drug development experience.","Preclinical data in EMBO Reports shows LB-100 can turn immunologically 'cold' tumors 'hot', enhancing immunotherapy benefit.","Small cell lung cancer trial at City of Hope terminated due to limited patient accrual; exploring alternative sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-033144","json":"https://secwatch.observer/filing/0001493152-24-033144.json","markdown":"https://secwatch.observer/filing/0001493152-24-033144.md","text":"https://secwatch.observer/filing/0001493152-24-033144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224033144/0001493152-24-033144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224033144/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:38:59.742485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}